Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide

Journal of Clinical Investigation

Volumn 111, Issue 9, 2003, Pages 1365-1371

  Martinez, Nathan R ^a   Augstein, Petra ^a   Moustakas, Antonis K ^b   Papadopoulos, George K ^b   Gregori, Silvia ^c   Adorini, Luciano ^c   Jackson, David C ^d   Harrison, Leonard C ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b Faculty of Agricultural Technology   (Greece)

^c ROCHE MILANO RICERCHE   (Italy)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROINSULIN B24 C36; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; BINDING AFFINITY; BINDING KINETICS; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK MANAGEMENT; TREATMENT OUTCOME;

ADMINISTRATION, INTRANASAL; ADOPTIVE TRANSFER; ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, TYPE 1; EPITOPES; FEMALE; HUMANS; MALE; MICE; MICE, INBRED NOD; MODELS, MOLECULAR; PEPTIDES; PROINSULIN; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0038814318     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317166     Document Type: Article

References (39)

1. Pugliese, A., et al. 1997. The insulin gene is transcribed in the human thymus and transcription levels correlate with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat. Genet. 15:293-297.
2. Vafiadis, P., et al. 2001. Class III alleles of the variable number of tandem repeat insulin polymorphism m associated with silencing of thymic insulin predispose to type 1 diabetes. J. Clin. Endocrinol. Metab. 86:3703-3710.
3. French, M.B., et al. 1997. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice [erratum 1997, 46:924]. Diabetes. 46:34-39.
4. Rudy, G., et al. 1995. Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol. Med. 1:625-633.
5. Chen, W., et al. 2001. Evidence that a peptide spanning the B-Cjunction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J. Immunol. 167:4926-4935.
6. Harrison, L.C., and Hafler, D.A. 2000. Antigen-specific therapy for autoimmune disease. Curr. Opin. Immunol. 12:704-711
7. Faria, A.M., and Weiner, H.L. 1999. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. 73:153-264.
8. Krause, I., Blank, M., and Shoenfeld, Y. 2000. Immunomodulation of experimental autoimnaune diseases via oral tolerance. Crit. Rev. Immunol 20:1-16.
9. Harrison, L.C., et al. 1997. A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H mice. J. Exp. Med. 185:1013-1021.
10. Rammensee, H.G., Bachmann, J., Emmerich, N., and Stevanovich, S. An Internet Database for MHC Ligands and Peptide Motifs. http://134.2.96.221/scripts/MHCserver.dll/home.htm.
11. Taylor, R., and Parker, K. An Internet Database for HLA Peptide Motifs. http://bimas.dcrt.nih.gov/.
12. Corper, A.L., et al. 2000. A structural framework for deciphering the link between 1-Ag7 and autoimmune diabetes. Science. 288:505-511.
13. Larek, R.R., et al., 2000. Structural basis of peptide binding and presentation by the type 1 diabetes-associated MHC class 11 molecule of NOD mice. Immunol. 12:699-710.
14. Moustakas, A.K., Routsias, J., and Papadopoulos, G.K. 2000. Modeling of the of the MHC II allele I-A(g7) of NOD mouse: pH-dependent changes in specificity at pockets 9 and 6 explain several of the unique properties of this molecule. Diabetologia. 43:609-624.
15. Frernont, D.H., Monnaie, D., Nelson, C.A., Hendrickson, W.A., and Unanue, E.R. 1998. Crystal structure of I-Ak in complex with a dominant epitope of lysozyme. Immunity. 8:305-317.
16. Madden, D.R., Garboczi, D.N., and Wiley, D.C. 1993. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell. 75:693-708.
17. Wong, F.S., Moustakas, A.K., Wen, L., Papadopoulos, G.K., and Janeway, C.A. 2002. Analysis of structure and function relationships of an autoantigenic peptide of insulin bound to H-2K(d) that stimulates CD8 T cells in insulin-dependent diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 99:5551-5556.
18. Mullbacher, A., and Lobigs, M. 1995. Up-regulation of MHC class I by flavivirus-induced peptide translocation into the endoplasmic reticulum. Immunity 3:207-214.
19. Sijts, A.J., and Palmer, E.G. 1997 Enhanced intracellular dissociation of major histocompatibility complex class I-associated peptides: a mechanism for optimizing the spectrum of cell surface-presented cytotoxic T lymphocyte epitopes. J. Exp. Med. 185:1403-1411.
20. Blanas, E., Carbone, F.R., Allison,J., Miller, J.F. and Heath, W.R. 1996. Induction of autoinamune diabetes by oral administration of auroantigen. Science. 274:1707-1709.
21. Clayton, J.P., et al. 1989. Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J. Exp. Med. 169:1681-1691.
22. Liblau, R., Tisch, R., Bercovici, N., and McDevitt, H.O. 1997. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol. Today 18:599-604.
23. Heeger, P.S., et al. 2000. Revisiting tolerance induced by autoantigen in incomplete Freund's adjuvant. J. Immunol. 164:5771-5781.
24. Bercovici, N., et al. 2000. Systemic administration of agonist peptide blocks the progression of spontaneous CD8-mediated autoimmune diabetes in transgenic mice without bystander damage. J. Immunol. 165:202-210.
25. Horig, H., Young, A.C., Papadopoulos, N.J., DiLorenzo T. P., and Nathenson, S.G. 1999. Binding of longer peptides to the H-2Kb heterodimer is restricted to peptides extended at their C terminus: refinement of the inherent MHC class I peptide binding criteria. J. Immunol. 165:4434-4441.
26. Wong, F.S., et al. 1999. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat. Med. 5:1026-1031.
27. Honeyman, M.C., Stone, N.L., and Harrison, L.C. 1998. T-cell epitopes in type 1 diabetes autoantigen tyrosine phosphatase IA-2: potential for mimicry with rotavirus and other environmental agents. Mol. Med. 4:231-239.
28. Takahashi, K., Honeyman, M.C., and Harrison, L.C. 2001. Cytotoxic T cells to an epitope in the islet autoantigen IA-2 are not disease-specific. Clin. Immunol. 99:360-364.
29. Quinn, A., McInerney, M.F., and Sercarz, E.E. 2001. MHC class I-restricted determinants on the glutamic acid decarboxylase 65 molecule induce spontaneous CTL activity. J. Immunol. 167:1748-1757.
30. Hanninen, A., Braakhuis, A., Heath, W.R., and Harrison, L.C. 2001. Mucosal antigen primes diabetogenic cytotoxic T-lymphocytes regardless of dose or delivery route. Diabetes. 50:771-775.
31. Kay, T.W.H., Parker, J.L., Stephens, L.A., Thomas, H.E., and Allison, J. 1996. RJP-beta 2-microglobulin transgene expression restores insulitis, but not diabetes, in beta 2-microglobulin null nonobese diabetic mice. J Immunol. 57:3688-3693.
32. Miller, A., Lider, O., Abramsky, O., and Weiner, H.L. 1994. Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. Eur. J. Immunol. 24:1026-1032.
33. Terato, K., Ye, X.J., Miyahara, H., Cremer,M.A., and Griffiths, M.M. 1996. Induction by chronic autoimmune arthritis in DBA/1 mice by oral administration of type II collagen and Eschertchia coli lipopolysaccharide. Br. J. Rheumatol. 35:828-838.
34. Bellmann, K., Kolb, H., Rastegar, S., Jee, P., and Scott, F.W. 1998. Potential risk of oral insulin with adjuvant for the prevention of Type I diabetes: a protocol effective in NOD mice may exacerbate disease in BB rats. Diabetologia. 41:844-847.
35. Weiner, H.L., et al. 1993. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science, 259:1321-1324.
36. McKown, K.M., et al. 1999. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum. 42:1204-1208.
37. Pozzilli, P., et al. 2000. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group. Diabetologia. 43:1000-10004.
38. Chaillous, L., et al. 2000. Oral insulin administration and residual betacell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale group. Lancet. 356:545-549.
39. Hanninen, A., Martinez, N.R., Davey, G.M., Heath, W.R., and Harrison, L.C. 2002. Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity. J. Clin. Invest. 109:261-267. doi:10.1172/JC1200213720.